AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04446715
Drug: meperidine
RxNorm normalized name: Meperidine
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive meperidine in spinal anesthesia
Trial: NCT04446715
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 0.5% heavy bupivacaine in spinal anesthesia
Trial: NCT00597714
Drug: Non-myeloablative Stem Cell Transplantation
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
Trial: NCT00170404
Drug: Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00170404
Drug: Selenium
RxNorm normalized name: Selenium
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02977299
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
Trial: NCT03082755
Drug: Gabapentin Enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
Trial: NCT00673608
Drug: deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
Trial: NCT00170404
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002463
Drug: Mechlorethamine Hydrochloride
RxNorm normalized name: Mechlorethamine hydrochloride
DrugBank: Mechlorethamine (DB00888)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002463
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01674322
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
Trial: NCT00130845
Drug: Octreotide Acetate in Microspheres
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03554304
Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet
Trial: NCT00624910
Drug: Bupivacaine Collagen Sponge (CollaRx®)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
Trial: NCT02573272
Drug: eslicarbacepine
RxNorm normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03375580
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5g metformin group，PO tid
Trial: NCT03375580
Drug: Compound Zhenzhu Tiaozhi capsule
RxNorm normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
Trial: NCT02369861
Drug: ST266
RxNorm normalized name: ST266
DrugBank: ST266 (DB18614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular application 4 times per day
Trial: NCT02265224
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The product was administered according to the randomisation list and cross-over design, with 150 mL of still mineral water under fasting conditions on study day 1 of periods 1 or 2 at 8:00±1 h.
Trial: NCT00910637
Drug: Gestodene/EE Patch (BAY86-5016)
DrugBank: Gestodene (DB06730)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles
Trial: NCT03338205
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg ketamine bolus IV
Trial: NCT03232320
Drug: Meditoxin
RxNorm normalized name: medigoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meditoxin (Botulinum toxin type A)
Trial: NCT03249376
Drug: Lumateperone
RxNorm normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone 42 mg (ITI-007 60 mg tosylate)
Trial: NCT02183870
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 250mg crizotinib bid until end of treatment
Trial: NCT01763788
Drug: Necitumumab
RxNorm normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT01763788
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT01763788
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02019784
Drug: Rifaximin-α
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
Trial: NCT02355522
Drug: Intrauterine lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02355522
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02355522
Drug: Intrauterine normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00321633
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00321633
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01620944
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, oral, 300 mg, Once daily (QD), 96 weeks
Trial: NCT01620944
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, oral, 100 mg, QD, 96 Weeks
Trial: NCT01256671
Drug: DHEA
RxNorm normalized name: DHEA
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
Trial: NCT02894996
Drug: fluid challenge
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
Trial: NCT02823964
Drug: Liprotamase
RxNorm normalized name: Liprotamase
DrugBank: Liprotamase protease (DB16584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
Trial: NCT00778245
Drug: cefprozil 500mg tablets
RxNorm normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002492
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01620944
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet, oral, 300 mg, QD, 96 Weeks
Trial: NCT01620944
Drug: Tenofovir/Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, oral, 300/200 mg, QD, 48 Weeks
Trial: NCT03554304
Drug: Moxifloxacin 400-mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400-mg positive control (overencapsulated tablet)
Trial: NCT03210064
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib Mesylate Tablets 500 mg qd po
Trial: NCT03210064
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
Trial: NCT04378114
Drug: Acetominophen
RxNorm normalized name: acetominophen 500 MG / dextromethorphan HBr 15 MG / doxylamine succinate 6.25 MG / pseudoephedrine HCl 30 MG per 15 ML Oral Solution
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One time administration of acetaminophen.
Trial: NCT02634502
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01445795
Drug: 200 mg INX-08189 Fasted
RxNorm normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg capsule INX-08189 fasted x7 days
Trial: NCT01445795
Drug: 100 mg INX-08189 QD
RxNorm normalized name: DNA (RECOMBINANT LENTIVIRUS VECTOR INXN-2004-TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
DrugBank: Dabocemagene autoficel (DB17878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg INX-08189 capsule QD x 7 days
Trial: NCT01445795
Drug: 100 mg INX-08189 BID Fasted
RxNorm normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg INX-08189 BID fasted x7 days
Trial: NCT01445795
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00575042
Drug: Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 mg per day for 1 year
Trial: NCT02185547
Drug: Zoloft
RxNorm normalized name: Zoloft
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline treatment 25 mg
Trial: NCT00996255
Drug: PHA-793887
RxNorm normalized name: PHA-793887
DrugBank: PHA-793887 (DB12686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
Trial: NCT00082602
Drug: galantamine ER
RxNorm normalized name: galantamine Extended Release Oral Capsule
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02854371
Drug: gadoxetic acid enhanced liver MRI
RxNorm normalized name: LIVER
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution.
Trial: NCT02854371
Drug: ICG R15
RxNorm normalized name: ICG 136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
Trial: NCT03846284
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
Trial: NCT03846284
Drug: Magnesium sulfate 50mg
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
Trial: NCT03846284
Drug: Magnesium sulfate 30 mg
RxNorm normalized name: magnesium sulfate 30 mg/mL-D5% intravenous solution
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h.
Trial: NCT01663558
Drug: imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02642380
Drug: Dexamethasone (4 cycles)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
Trial: NCT02642380
Drug: Dexamethasone (1 cycle)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 40mg daily for 4 consecutive days
Trial: NCT01898013
Drug: Pregnenolone
RxNorm normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00619268
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg once per week administered intravenously
Trial: NCT00619268
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg \* 1 time /2 weeks administered intravenously
Trial: NCT00619268
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
Trial: NCT00770224
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01090908
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01311362
Drug: St. Johns wort
RxNorm normalized name: St. johns wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~* Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20
Trial: NCT02826018
Drug: Sterile Normal Saline (0.9% NaCl)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calculated volume to match active comparator
Trial: NCT01393080
Drug: Nimotuzumab and TP regimen
RxNorm normalized name: Anacin Aspirin Regimen
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~2. Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression.
Trial: NCT00464919
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00464919
Drug: tegafur/uracil (UFUR®)
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00619268
Drug: Interferon alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously as 9 MU three times per week
Trial: NCT03616964
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT00568841
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
Trial: NCT00004146
Drug: carboxyamidotriazole
RxNorm normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03257423
Drug: Ertapenem followed by levofloxacin and metronidazole
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
Trial: NCT03257423
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
Trial: NCT00888342
Drug: supplementary oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplementary oxygen 2 L/min if SpO2 \< 90%. If SpO2 \< 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
Trial: NCT01699464
Drug: Timolol maleate ophthalmic solution 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ophthalmic Solution
Trial: NCT00525928
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
Trial: NCT01266018
Drug: ADI-PEG 20 (Arginine deiminase pegylated)
RxNorm normalized name: PEG-20 stearate
DrugBank: Pegargiminase (DB06592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
Trial: NCT01951404
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00950196
Drug: amantadine sulphate
RxNorm normalized name: Amantadine sulphate
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
Trial: NCT01045863
Drug: PF-03382792 Cohort 1
RxNorm normalized name: PF-03382792
DrugBank: PF-03382792 (DB12949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
Trial: NCT01045863
Drug: PF-03382792 Cohort 2
RxNorm normalized name: chloroprocaine
DrugBank: PF-03382792 (DB12949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
Trial: NCT01045863
Drug: PF-03382792
RxNorm normalized name: PF-03382792
DrugBank: PF-03382792 (DB12949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
Trial: NCT01045863
Drug: Food Effect cohort
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
Trial: NCT01045863
Drug: CSF cohort
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
Trial: NCT00888342
Drug: zopiclone
RxNorm normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg sedative given approximately 1 hour before sleep
Trial: NCT00770224
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02684123
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will get drug or placebo